Find Endocrinology Drugs in Phase II Clinical Development

Lead Product(s): O304

Therapeutic Area: Endocrinology

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Ivy Capital

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding January 20, 2020

Details:

The funding and connections within the Chinese Biotech and Pharmaceutical markets, will be important to support a speedy and global development of O304X in several major indications.

Lead Product(s): NT-814

Therapeutic Area: Endocrinology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Phase 2b dose range finding study showed rapid and highly significant reductions in the frequency of hot flashes (primary endpoint) for the full 12-week treatment period.

Lead Product(s): Glucagon

Therapeutic Area: Endocrinology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 06, 2020

Details:

Results show a mini dose (150 µg) of RTU glucagon prevents Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a clinical research setting.